BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 28422287)

  • 1. Genetic variants as potential predictive biomarkers in advanced colorectal cancer patients treated with oxaliplatin-based chemotherapy.
    Bahrami A; Amerizadeh F; Hassanian SM; ShahidSales S; Khazaei M; Maftouh M; Ghayour-Mobarhan M; Ferns GA; Avan A
    J Cell Physiol; 2018 Mar; 233(3):2193-2201. PubMed ID: 28422287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SNPs in transporter and metabolizing genes as predictive markers for oxaliplatin treatment in colorectal cancer patients.
    Kap EJ; Seibold P; Scherer D; Habermann N; Balavarca Y; Jansen L; Zucknick M; Becker N; Hoffmeister M; Ulrich A; Benner A; Ulrich CM; Burwinkel B; Brenner H; Chang-Claude J
    Int J Cancer; 2016 Jun; 138(12):2993-3001. PubMed ID: 26835885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic variants in DNA repair genes as potential predictive markers for oxaliplatin chemotherapy in colorectal cancer.
    Kap EJ; Seibold P; Richter S; Scherer D; Habermann N; Balavarca Y; Jansen L; Becker N; Pfütze K; Popanda O; Hoffmeister M; Ulrich A; Benner A; Ulrich CM; Burwinkel B; Brenner H; Chang-Claude J
    Pharmacogenomics J; 2015 Dec; 15(6):505-12. PubMed ID: 25778469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review of excision repair cross-complementation group 1 in colorectal cancer.
    Bohanes P; Labonte MJ; Lenz HJ
    Clin Colorectal Cancer; 2011 Sep; 10(3):157-64. PubMed ID: 21855036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy.
    De Mattia E; Cecchin E; Toffoli G
    Drug Resist Updat; 2015 May; 20():39-70. PubMed ID: 26027741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ERCC5 promoter polymorphisms at -763 and +25 predict the response to oxaliplatin-based chemotherapy in patients with advanced colorectal cancer.
    Chen J; Xie F; Chen K; Wang D; Jiang H; Li J; Pan F; Chen S; Zhang Y; Ruan Z; Huang H; Zou L; Liang H
    Cancer Biol Ther; 2009 Jul; 8(14):1424-30. PubMed ID: 19458483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-Related Molecular Mechanisms of Oxaliplatin Resistance.
    Martinez-Balibrea E; Martínez-Cardús A; Ginés A; Ruiz de Porras V; Moutinho C; Layos L; Manzano JL; Bugés C; Bystrup S; Esteller M; Abad A
    Mol Cancer Ther; 2015 Aug; 14(8):1767-76. PubMed ID: 26184483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. XRCC1 and GSTP1 polymorphisms and prognosis of oxaliplatin-based chemotherapy in colorectal cancer: a meta-analysis.
    Ye F; Liu Z; Tan A; Liao M; Mo Z; Yang X
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):733-40. PubMed ID: 23299794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic variants in the glutathione S-transferase genes and survival in colorectal cancer patients after chemotherapy and differences according to treatment with oxaliplatin.
    Kap EJ; Richter S; Rudolph A; Jansen L; Ulrich A; Hoffmeister M; Ulrich CM; Brenner H; Chang-Claude J
    Pharmacogenet Genomics; 2014 Jul; 24(7):340-7. PubMed ID: 24842074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR-34a mediates oxaliplatin resistance of colorectal cancer cells by inhibiting macroautophagy
    Sun C; Wang FJ; Zhang HG; Xu XZ; Jia RC; Yao L; Qiao PF
    World J Gastroenterol; 2017 Mar; 23(10):1816-1827. PubMed ID: 28348487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxaliplatin-based chemotherapy in the management of colorectal cancer.
    Capdevila J; Elez E; Peralta S; Macarulla T; Ramos FJ; Tabernero J
    Expert Rev Anticancer Ther; 2008 Aug; 8(8):1223-36. PubMed ID: 18699761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A platinum agent resistance gene, POLB, is a prognostic indicator in colorectal cancer.
    Iwatsuki M; Mimori K; Yokobori T; Tanaka F; Tahara K; Inoue H; Baba H; Mori M
    J Surg Oncol; 2009 Sep; 100(3):261-6. PubMed ID: 19330779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Irinotecan or oxaliplatin combined with 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer: a meta-analysis.
    Liang XB; Hou SH; Li YP; Wang LC; Zhang X; Yang J
    Chin Med J (Engl); 2010 Nov; 123(22):3314-8. PubMed ID: 21163137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy.
    Kweekel DM; Gelderblom H; Guchelaar HJ
    Cancer Treat Rev; 2005 Apr; 31(2):90-105. PubMed ID: 15847979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nucleotide excision repair and response and survival to chemotherapy in colorectal cancer patients.
    Kap EJ; Popanda O; Chang-Claude J
    Pharmacogenomics; 2016 May; 17(7):755-94. PubMed ID: 27183147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of a comprehensive panel of biomarkers to predict response to a fluorouracil-oxaliplatin regimen in patients with metastatic colorectal cancer.
    Lamas MJ; Duran G; Balboa E; Bernardez B; Touris M; Vidal Y; Gallardo E; Lopez R; Carracedo A; Barros F
    Pharmacogenomics; 2011 Mar; 12(3):433-42. PubMed ID: 21449681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PML as a potential predictive factor of oxaliplatin/fluoropyrimidine-based first line chemotherapy efficacy in colorectal cancer patients.
    Vincenzi B; Santini D; Perrone G; Graziano F; Loupakis F; Schiavon G; Frezza AM; Ruzzo AM; Rizzo S; Crucitti P; Galluzzo S; Zoccoli A; Rabitti C; Muda AO; Russo A; Falcone A; Tonini G
    J Cell Physiol; 2012 Mar; 227(3):927-33. PubMed ID: 21503888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RNA-seq identifies determinants of oxaliplatin sensitivity in colorectal cancer cell lines.
    Li XX; Peng JJ; Liang L; Huang LY; Li DW; Shi DB; Zheng HT; Cai SJ
    Int J Clin Exp Pathol; 2014; 7(7):3763-70. PubMed ID: 25120752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA repair genes XPC, XPG polymorphisms: relation to the risk of colorectal carcinoma and therapeutic outcome with Oxaliplatin-based adjuvant chemotherapy.
    Liu D; Wu HZ; Zhang YN; Kang H; Sun MJ; Wang EH; Yang XL; Lian MQ; Yu ZJ; Zhao L; Olopade OI; Wei MJ
    Mol Carcinog; 2012 Oct; 51 Suppl 1():E83-93. PubMed ID: 22213216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical efficacy of oxaliplatin monotherapy: phase II trials in advanced colorectal cancer.
    Becouarn Y; Rougier P
    Semin Oncol; 1998 Apr; 25(2 Suppl 5):23-31. PubMed ID: 9609105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.